High level secretion of a humanized bispecific diabody from Escherichia coli

Bio/Technology

Volumn 14, Issue 2, 1996, Pages 192-196

  Zhu, Zhenping ^a   Zapata, Gerardo ^a   Shalaby, Refaat ^b   Snedecor, Brad ^c   Chert, Man ^d   Carter, Paul ^d  

^a Departments of 1 Molecular Oncology

^b Process Sciences   (United States)

^c Bioanalytical Technology   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; DRUG RESEARCH; DRUG SCREENING; DRUG SYNTHESIS; ESCHERICHIA COLI; HUMAN; NONHUMAN; T LYMPHOCYTE; SECRETION;

AMINO ACID SEQUENCE; ANTIBODIES, BISPECIFIC; ANTIGEN-ANTIBODY REACTIONS; BASE SEQUENCE; CHROMATOGRAPHY, GEL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ESCHERICHIA COLI; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; SECRETORY RATE; T-LYMPHOCYTES, CYTOTOXIC; TITRIMETRY; TUMOR CELLS, CULTURED;

ESCHERICHIA COLI;

EID: 0030039532     PISSN: 0733222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0296-192     Document Type: Article

References (31)

1. Malavasi, F,. De Monte, L. B., Funaro, A., Magrini, E., Bonino, L. D., Momo, M., Mariani, M., Horenstein, A. and Natali, P. G. 1993. Cell surface receptors and bispecific monoclonal antibodies: the link between science and medical oncology. Year Immunol. 7:74-80.
2. Fanger, M. W., Morganelli, P. M. and Guyre, P. M. 1993. Use of bispecific antibodies in the therapy of tumors, p. 181-194. In: Immunoconjugate Therapy of Hématologie Maligancies, Rosen, Steven, T. and Kuzel, T. M. (Eds.). Kluwer Academic Publishers.
3. Milstein, C. and Cuello, A. C. 1983. Hybrid hybridomas and their use in immunohistochemistry. Nature 305:537-540.
4. Brennan, M., Davison, P. F. and Paulus, H. 1985. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin Gl fragments. Science 229:81-83.
5. Glennie, M. J., McBride, H. M., Worth, A. T. and Stevenson, G. T. 1987. Preparation and performance of bispecific F(ab'7), antibody containing thiother-Iinked Fab'-y fragments. J. Immunol. 139:2367-2375.
6. Holliger, H. and Winter, G. 1993. Engineering bispecific antibodies. Curr. Opin. Biotech. 4:446-449.
7. Carter, P., Ridgway, J. and Zhu, Z. 1995. Toward the production of bispecific antibody fragments for clinical applications. J. Hematotherapy 4:463-470.
8. Holliger, P., Prospero.T. and Winter, G. 1993. Diabodies: small bivalent and bispecific antibody fragments. Proc. Natl Acad. Sci. USA 90:6111 6448.
9. Desplancq, D., King, D. J., Lawson, A. D. G. and Mountain, A. 1994. Multimerization behaviour of single chain Fv variants for the tumor-binding antibody B72.3. Protein Eng. 7:1027-1033.
10. Whitlow, M., Rlpula, D., Rollence, M. L., Feng, S. L. and Wood, J. F. 1994. Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv. Protein Eng. 7:1017-1026.
11. Shalaby, M. R-, Shepard, H. M., Presta, L., Rodrigues, M., Beverley, P. C. L., Feldmann, M. and Carter, P. 1992. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J. Exp. Med. 175:217-225.
12. Rodrigues, M. L., Shalaby, M. R., Werther, W., Presta, L. and Carter, P. 1992. Engineering a humanized bispecific F(ab')l fragment for improved binding to T cells. Int. J. Cancer (Suppl.) 7:45-50.
13. Shalaby, M. R., Carter, P., Maneval, D., Giltinan, D. and Kotts, C. 1995. Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to IIER2 overexpressing xenografts in nude mice. Clin. Immunol. Immunopath. 74:185-192.
14. Zhu, Z., Lewis, G. D. and Carter, P. 1995. Engineering high affinity humanized anti-p185HER2/anti-CDS bispecific F(ab')2 for efficient lysis of pl85HOU overexpression tumor cells. Int. J. Cancer 62. 319-324.
15. Carter, P., Kelley, R. F., Rodrigues, M. L., Snedccor, B., Covarrubias, M., Velligan, M. D., Wong, W. L. T., Rowland, A. M., Kotts, C. E., Carver, M. E., Yang, M., Bourell, J. H., Shepard, H. M. and Henncr, D. 1992. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio/Technology 10:163-167.
16. Bolivar, F., Rodriguez, R. L., Greene, P. J., Betlach, M. C., Heyneker, H. L., Boyer, H. W., Crosa, J. H. and Falkow, S. 1977. Construction and characterization of new cloning vehicles. II. A multipurpose cloning system. Gene 2:95-113.
17. Chang, C. N., Kuang, W.-J. and Chen, E. Y. 1986. Nucleotide sequence of the alkaline phosphatase gene of Escherichia coli. Gene 44:121-125.
18. Picken, R. N., Mazaitis, A. J., Maas, W. K., Rey, M. and Heyneker, H. 1983. Nucleotide sequence of the gene for heat-stable enterotoxin II of Escherichia coli. Infect. Immun. 42:269-275.
19. Rodrigues, M. L., Presta, L., Kotts, C, Wirth, C., Mordenti, J., Osaka, G., Wong, W. L. T., Nuijens, A., Blackburn, B. and Carter, P. 1995. Development of a humanized disulfide-stabilized anti-pi8511 Fv-β-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res. 55:63-70.
20. Rodrigues, M. L., Snedecor, B., Chen, C., Wong, W. L. T., Garg, S., Blank, G. S., Maneval, D. and Carter, P. 1993. Engineering Fab' fragments for efficient F(ab')- formation in Escherichia coli and for improved in vira stability. J. Immunol. 151:6954-6991.
21. Perisic, O., Webb, P. A., Holliger, P., Winter, G. and Williams, R. L. 1994. Crystal structure of a diabody, a bivalent antibody fragment. Structure 2:1217-1226.
22. Eigenbrot, C, Randal, M., Presta, L., Carter, P. and Kossiakoff, A. 1993. X-ray structures of the antigen-binding domains from three variants of humanized anti-pl85HrR: antibody 4D5 and comparison with molecular modelling. J. Mol. Biol. 229:969-995.
23. Ulrich,H.D.,Yang,P.Y.,Patten,P.A.,Romesberg,F.E.andSchultz,P.G. 1995. Expression studies of catalytic antibodies.. Proc. Natl Acad. Sci. USA In press.
24. Knappik, A. and Plückthun, A. 1995. Engineered turns of recombinant antibody improve its in vivo folding. Protein Engin. 8:81-89.
25. Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B. B., Henner, D., Wong, W. L. T., Rowland, A. M., Kotts, C., Carver, M. E. and Shepard, H. M. 1992. Humanization of an anti-pi85H1JU antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89:4285-4289.
26. Sanger, F., Nicklen, S., and Coulson, A. R. 1977. DNA sequencing with chainterminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467.
27. Fendly, B. M., Kotts, C., Vetterlein, D., Lewis, G. D., Winget, M., Carver, M. E., Watson, S. R., Sarup, J., Saks, S., Ullrich, A. and Shepard, H. M. 1990. The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J. Biol. Resp. Mod. 9:449-455.
28. Zapata, G., Ridgway, J. B. B., Mordenti, J., Osaka, J., Wong, W. L. T., Bennett, G. and Carter, P. 1995. Engineering linear F(ab'); fragments. Protein Engineering. In press.
29. Kelley, R. F. and O'Connell, M. P. 1993. Thermodynamics of an antibody functional epitope. Biochemistry 32:6828-6835.
30. Zhu, Z. and Carter, P. 1995. Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation. J. Immunol. 155:1903-1910.
31. Kabat, E. A., Wu, T. T., Perry, H. M., Gottesman, K. S. and Foeller, C. 1991. Sequences of Proteins of Immunological Interest, Ed. 5. National Institutes of Health, Bethesda, MD.